NVCT — Nuvectis Pharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1875558 ·
Last close
$19.20
Market Cap
$660.27M
52W High
$29.27
52W Low
$5.77
ADV30
198,530
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -31,049,000 -30,070,000 140,839,000 140,707,000 14,193,000
Jun 2026 0 — -7,197,000 -7,020,000 22,376,000 22,160,000 13,294,000
Mar 2026 0 — -6,260,000 -6,050,000 25,398,000 25,130,000 11,178,000
Dec 2025 0 — -7,617,000 -7,314,000 31,709,000 31,634,000 13,296,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-40,294,000
Investing CF
$0
Financing CF
$145,559,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.02
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-142,827,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-52,123,000
Pretax Income TTM
$-50,454,000
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -27,574,000 -26,442,000 31,709,000 13,296,000 18,413,000 -16,009,000
Dec 2024 0 -19,847,000 -19,000,000 18,607,000 8,894,000 9,713,000 -12,247,000
Dec 2023 0 -22,897,000 -22,260,000 19,185,000 6,984,000 12,201,000 -15,954,000
Dec 2022 0 -19,234,000 -19,085,000 20,405,000 6,186,000 14,219,000 -13,559,000

TTM Snapshot

Revenues TTM
$6,514,000
NetIncome TTM
$-27,846,000
OpCashFlow TTM
—
Assets (Latest)
$22,376,000
Forward EPS
$-0.96

Max Pain — expiry 2027-01-15

max pain strike: $15.00 · spot: $20.29 · call oi: 1,464 · put oi: 19
Expected Move to 2027-01-15: ±$5.53 (27.23%) — implied range $14.76 – $25.81 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ANNX Annexon, Inc. $661.95M $3.47 —
JANX Janux Therapeutics, Inc. $655.27M $10.71 —
GERN GERON CORP $644.24M $1.00 —
SVA SINOVAC BIOTECH LTD $642.44M $6.47 —
BCAX Bicara Therapeutics Inc. $637.32M $9.60 —

News headlines (Yahoo Finance, 1h cache)

Nuvectis Pharma, Inc. Q3 2026 Earnings Call Summary
2026-11-04 23:24 · Yahoo
Nuvectis Pharma Inc (NVCT) (Q3 2026) Earnings Call Highlights: Late-Stage Transformation, $140 ...
2026-11-04 21:06 · Yahoo
Nuvectis (NVCT) Q3 2026 Earnings Call Transcript
2026-11-04 17:17 · Yahoo
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-04 12:00 · Yahoo
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
2026-11-02 22:00 · Yahoo
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
2026-10-26 12:30 · Yahoo
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
2026-10-09 12:00 · Yahoo
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
2026-09-24 12:00 · Yahoo
Nuvectis Pharma To Participate in Upcoming Investor Conferences
2026-09-03 12:00 · Yahoo
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
2026-08-19 15:33 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.